In recent hours, Denmark was the first of the countries in Europe to announce the announcement of the two-week suspension, starting Thursday, of the application of the AstraZeneca vaccine following a series of reports of blood clots among patients. Local Health Minister Magnus Heunicke was in charge of officially reporting the Nordicee’s position and noted that this is a “precautionary measure.” “We act early, it needs to be thoroughly investigated,” mimsmo said before an official statement.
Discontinue the application of the AstraZeneca vaccine in some countries in Europe.
The director of the National Health Board, S. Brostrom, extended his colleague’s sayings and noted that it was not taken lightly. “We are in the midst of the largest and most important vaccination launch in Denmark’s history. And right now we need all the vaccines we can get. Therefore, putting one of the vaccines on pause is not an easy decision.” We must respond with timely attention when we are aware of possible serious side effects. We need to clarify this before we can continue to use the AstraZeneca vaccine,” he said, explaining that it does not jeopardize the lab product.” It is important to emphasize that we have not opted out of the AstraZeneca vaccine, but that we are suspending it. There is good evidence that the vaccine is safe and effective,” they stressed. However, the investigation takes a few days and the decision affected other nations.
Iceland and Norway followed suit, but did not say how long their suspensions would last, although only one of them recorded a single case of clotting. Kjartan Njálsson, assistant director of health in Iceland, said there were no reports of patients waiting for the advice of the European Medicines AgencyThe Norwegian Institute of Public Health, on the other hand, cases had been reported shortly after receiving the covid-19 vaccine in Norway, but noted that it occurred “mainly in the elderly, where there is often also another underlying disease”. A set of AstraZeneca vaccines is in the sights of the European Union authorities. On the same Thursday, Italy joined Austria, Estonia, Lithuania, Luxembourg and Latvia to discontinue dose use of the ABV5300 batch which will be evaded and delay vaccination.
